As per the report, the size of the Europe Hemophilia Management Market was worth USD 1299.71 million in 2021 and estimated to be growing at a CAGR of 1.54%, to reach USD 1402.92 million by 2026.
Hemophilia is a genetic disorder that impairs the body`s ability to control blood clotting. Hemophilia usually occurs in males it is estimated that about 1 in 5000 males that are born each year contain hemophilia. Hemophilia is categorized into three levels depending on its severity as severe, moderate and mild. About 80% of the hemophilia patients are considered to suffer from severe type. The worldwide incidence of hemophilia is estimated at more than 400,000 people.
Europe Hemophilia Management market is driven by factors such as the growing prevalence of hemophilia A and hemophilia B, increasing government support and increasing usage of recombinant products. Technological advancements along with rising investments in Research and developments for hemophilia products are also some of the key factors fuelling the growth of the market.
However stringent regulatory policies, lack of available medication high cost of treatment are the major factors hindering the growth of the market. Advancements in gene therapy and approaching approval of drugs for treatment of hemophilia provide immense growth opportunities in the market.
This research report on the Europe Hemophilia Management Market is segmented and sub-segmented into the following categories:
By Type:
By Drug:
By Country:
Regionally, Europe is the second-largest market for hemophilia management. Within Europe, the United Kingdom is the largest market for hemophilia management accounting for a share of approximately XX% due to huge government support. Germany is estimated to be the fastest-growing region with the highest CAGR of XX% owing to increasing disease burden.
Most promising companies in Europe Hemophilia Management Market profiled in this report are Biogen, Baxter International Inc., Pfizer Inc., Bayer Pharma AG, Novo Nordisk A/S, Grifols International SA, CSL Behring, Octapharma and Swedish Orphan Biovitrum AB
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 BY Type
5.1.1 Hemophilia A
5.1.2 Hemophilia B
5.2 By Drug
5.2.1 Octocogalfa
5.2.2 Nonacogalfa
5.2.3 Desmopressin
5.2.4 Other drugs
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Biogen
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Pfizer Inc.
8.3 Baxter International Inc.
8.4 Bayer Pharma AG
8.5 Novo Nordisk A/S
8.6 Grifols International SA
8.7 CSL Behring
8.8 Octapharma
8.9 Swedish Orphan Biovitrum AB
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
